or Try an Advanced Search...

    Technical Analysis for MORF - Morphic Holding, Inc.

    Grade Last Price % Change Price Change
    F 29.23 -9.92% -3.22
    MORF closed down 9.92 percent on Friday, May 17, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    Earnings due: May 31
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical MORF trend table...
    Date Alert Name Type % Chg
    Bearish Engulfing Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    20 DMA Support Bullish 0.00%
    Wide Range Bar Range Expansion 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Multiple of Ten Bearish Other 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    200 DMA Resistance Bearish -9.92%
    Crossed Above 50 DMA Bullish -9.92%
    Expansion Pivot Buy Setup Bullish Swing Setup -9.92%
    Older End-of-Day Signals for MORF ...

       Recent Intraday Alerts

    Alert Time
    20 DMA Support 1 day ago
    Down 10% 1 day ago
    Down 2 ATRs 1 day ago
    10 DMA Support 1 day ago
    Fell Below Previous Day's Low 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MORF Chart by TradingView
    Basic chart:

    Profile

    Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Integrin

    Is MORF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Morphic to Participate in RBC Capital Markets Global Healthcare Conference
    May 1 Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
    Apr 26 Morphic Holding files automatic mixed shelf
    Apr 25 Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review
    Apr 25 Morphic GAAP EPS of -$0.91
    Apr 25 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
    Apr 24 What Makes Morphic (MORF) a New Buy Stock
    Mar 21 Morphic Holding Insiders Placed Bullish Bets Worth US$47.3m
    Mar 19 Morphic appoints Simon Cooper as CMO
    Mar 19 Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
    See more MORF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 63.0825
    52 Week Low 19.345
    Average Volume 436,257
    200-Day Moving Average 33.12
    50-Day Moving Average 30.89
    20-Day Moving Average 28.97
    10-Day Moving Average 29.65
    Average True Range 1.73
    RSI (14) 48.19
    ADX 23.05
    +DI 26.80
    -DI 17.67
    Chandelier Exit (Long, 3 ATRs) 28.67
    Chandelier Exit (Short, 3 ATRs) 31.56
    Upper Bollinger Bands 31.30
    Lower Bollinger Band 26.63
    Percent B (%b) 0.56
    BandWidth 16.12
    MACD Line -0.10
    MACD Signal Line -0.45
    MACD Histogram 0.3438
    Fundamentals Value
    Market Cap 1.45 Billion
    Num Shares 49.7 Million
    EPS -3.29
    Price-to-Earnings (P/E) Ratio -8.88
    Price-to-Sales 296.69
    Price-to-Book 2.73
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 34.89
    Resistance 3 (R3) 35.41 34.06 33.94
    Resistance 2 (R2) 34.06 32.62 33.79 33.63
    Resistance 1 (R1) 31.64 31.73 30.97 31.12 33.31
    Pivot Point 30.29 30.29 29.95 30.02 30.29
    Support 1 (S1) 27.87 28.85 27.20 27.35 25.15
    Support 2 (S2) 26.52 27.96 26.25 24.83
    Support 3 (S3) 24.10 26.52 24.52
    Support 4 (S4) 23.58